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Abstract
Schizophrenic patients have higher smoking rates than the general population. Studies show that smoking may be a form
of self-medication in an attempt to alleviate cognitive deficits in schizophrenic patients of European background. This study
examined the relationships between smoking and cognitive deficits in Chinese schizophrenic patients, which have
previously received little systemic study. We recruited 580 male chronic patients meeting DSM-IV criteria for schizophrenia
and 175 male control subjects who were matched on age and education. The subjects completed a detailed cigarette
smoking questionnaire, the Fagerstrom Test for Nicotine Dependence (FTND), and the Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS). Patients also were rated on the Positive and Negative Symptom Scale
(PANSS), the Simpson and Angus Extrapyramidal Symptom Rating Scale (SAES), and the Abnormal Involuntary Movement
Scale (AIMS). All five RBANS subscales except for the Visuospatial/Constructional index showed significantly lower cognitive
performance for schizophrenics than normal controls. The schizophrenic smokers scored lower than the schizophrenic non-
smokers on the RBANS total score and the Visuospatial/Constructional and Immediate Memory indices. Similarly, the control
smokers scored lower than the control non-smokers on the RBANS total score and the Immediate Memory index . Also, the
schizophrenic smokers consistently performed the poorest on the cognitive domains of the RBANS. Among the
schizophrenic patients, smokers displayed significantly fewer negative symptoms than non-smokers. Using multivariate
regression analysis the following variables were independently associated with the RBANS total score: years of education,
PANSS negative symptom score, age at schizophrenia onset, and number of hospitalizations. Our results show that smoking
is associated with significant cognitive impairment in both schizophrenic patients and normal controls, but the smokers
with schizophrenia had a reduced level of negative symptoms, suggesting that the benefits of smoking for those with
schizophrenia may be limited to certain aspects of a given clinical phenotype.
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Introduction
Schizophrenia is a severe psychiatric disorder characterized by
multi-faceted deficits in neurocognitive function, including learn-
ing, memory, attention, executive functioning and cognitive
processing speed [1–4]. Cognitive impairment is an enduring
feature of schizophrenia [5] which is often present at illness onset
[6,7] and persists regardless of a change in patients’ symptom state
[8]. Cognitive impairments are major impediments to social
rehabilitation and predict poor clinical outcome in patients with
schizophrenia [2]. However, lack of effective treatment by
currently available medications for cognitive symptoms remains
a major unmet need in the management of schizophrenia. Hence,
cognition has become a prime treatment target in schizophrenia
[9].
Schizophrenia has a higher rate of cigarette smoking than
patients with other psychiatric diagnoses and the general
population [10–14]. Furthermore, smokers with schizophrenia
may also have higher daily cigarette consumption, favor stronger
cigarettes and extract more nicotine from their cigarettes [15,16]
than normal smokers. These observations remain true across
cultures and countries and when controlling for possible
confounds, such as marital and socio-economic status, alcohol
use, antipsychotic use, or institutionalism [12,17]. Some studies
indicate that cigarette smoking or nicotine may ameliorate some of
the cognitive deficits in schizophrenic patients [18–23] or may
normalize deficits in auditory sensory gating in both schizophrenia
and their first-degree relatives [24–26], suggesting that cigarette
smoking or nicotine serves as a form of self-medication [27–30].
This observation also suggests that a dysfunction in nicotinic
acetylcholine receptor signaling may be involved in the etiology of
cognitive deficits in schizophrenia [31,32].
Although evidence suggests that smoking may ameliorate a
number of cognitive deficits associated with schizophrenia, the
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under-examined among Chinese patients. To date, there has been
no published study reporting this association. This is surprising
since 67% and 56% of males and 7% and 6% of females were
ever-smokers or current smokers respectively [33]. In addition,
gender is a major determinant of smoking behaviors in all
countries [12], although the gap between smoking rates in men
and women, both with and without schizophrenia, has lessened
considerably in North American and European countries [17].
However, in China, female smoking is extraordinarily rare in both
general population (male/female: 67.1% vs 7.1%) [33], and in
patients with schizophrenia (male/female: 81% vs 5%) [14]. Thus,
we focused on male subjects in this study. The purpose of this
study therefore was to determine if smoking was associated with
improved cognitive functioning in a large Han Chinese schizo-
phrenic inpatient population.
Methods
Ethics Statement
After a complete description of the study, all subjects gave their
written informed consent to participate in the study. The protocol
was approved by the Institutional Review Board (IRB), Beijing
HuiLongGuan hospital.
To test whether the participants had the capacity to consent a
psychiatrist evaluated them. The psychiatrists explained the
research procedure to the subject and ensured that the research
participants understood what they were being asked to do in the
study through specific questions about research processes and this
specific interview study. The explanation was tailored to maximize
the understanding of the subject by using language appropriate to
the subject’s level of comprehension, and emotional readiness. If
he/she was willing to assent to participate in research but was not
able to understand the complexity of research processes, the
researcher described presenting the parents or guardians and the
subject with the same information at the same time. The parents
or guardians then helped to explain the study procedures to the
subject, gauging the subject’s interest, and maximizing her/his
understanding. In this situation, the subject’s parents or guardians
gave their written consent on the behalf of the subject.
Subjects
Five hundred and eighty male schizophrenic inpatients were
recruited from Beijing Hui-Long-Guan hospital, a Beijing-city-
owned psychiatric hospital, and HeBei Province Veteran Psychi-
atric Hospital in BaoDing city, which is about 50 miles away from
Beijing. All patients met the following inclusion criteria: 1) age 25–
75 years, Han Chinese; 2) confirmed DSM-IV diagnosis of
schizophrenia; 4) with at least 5 years of illness; 5) had been
receiving stable doses of oral antipsychotic drugs for at least 12
months before entry into the study. All patients were of the chronic
type, with a mean illness course of 24.767.6 years and with a
mean duration of 7.666.8 years on current antipsychotic
treatment. Patients were hospitalized for an average of 9.167.2
years. Since admission, all patients received dietetically balanced
hospital meals, which were occasionally supplemented by gifts
(usually fruit); patients had the opportunity for about an hour of
physical exercise every day. Since these patients were hospitalized,
there were restrictions on their smoking, with a fixed schedule for
smoking: three or four times each day, and 30 minutes each time.
During the smoking period, a patient could smoke as many
cigarettes as he/she liked. The patients or their family members
had to purchase the cigarettes, with occasional supplemented
supplies from their friends or employers, but at very low prices for
most cigarette brands. Thus, smoking was not economically
limited, and for the assessment period of these baseline smoking
behaviors no patients were engaged in any behavior reinforcement
schedules using cigarettes. The patients in the present study could
be considered a representative sample of institutionalized chronic
patients with schizophrenia in China.
Age- and education-matched control subjects (n=175) were
recruited from the local community in Beijing. Current mental
status and personal or family history of any mental disorder was
assessed by unstructured interviews. None of the healthy control
subjects presented a personal or family history of psychiatric
disorder. All subjects were Han Chinese recruited at the same
period from the Beijing area. Demographic data for patients and
normal controls are summarized in Table 1.
A complete medical history, physical examination and labora-
tory tests were obtained from patients and control subjects. All
were in good physical health. Any subjects with any abnormalities
whatsoever were excluded, including 5 patients and 3 healthy
controls due to cardiovascular disease, 4 patients and 3 healthy
controls due to cerebrovascular disease, 3 patients and 2 healthy
controls due to severe infections, and 2 patients and 2 healthy
controls due to cancer. Neither schizophrenic nor control subjects
were currently drug or alcohol abusers or dependent.
Measures
Each subject filled out a detailed questionnaire that recorded
general information, sociodemographic characteristics, smoking
behavior, and medical and psychological conditions. In addition, a
cigarette smoking questionnaire was used to record smoking
history and family history of smoking from the patient and verified
by family members. The Chinese translation of the standardized
Fagerstrom Test for Nicotine Dependence (FTND) was employed
to measure the degree of nicotine dependence [34]. Additional
information was collected from available medical records and
collateral data (from family and/or treating clinician). Additional
visits were requested for subjects with missing or ambiguous data.
The subjects were divided into different groups based on their
smoking history and the FTND scores. Never smokers were defined
as individuals who had smoked less than 100 cigarettes during
their lifetime. Former smokers were defined as persons who had
previously smoked more than one cigarette each day but had quit
smoking for more than 1 year. Current smokers were defined as
persons who smoked one cigarette or more each day and have
smoked for more than 1 year. Ever smokers included current and
former smokers. Smoking cessation rates were measured as the
ratio of former smokers to the total subjects.
Table 1. Demographics of male patients and male control
subjects.
Category Schizophrenia N=580 Controls N=175
Age (years) 47.469.6 47.8612.2
Education (years) 9.662.3 9.563.1
Smoking
Current smoker 456(78.6%) 96(54.8%)
Former smoker 20(3.5%) 18(10.3%)
Never smoker 104(17.9%) 61(34.9%)
doi:10.1371/journal.pone.0036563.t001
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The Repeatable Battery for the Assessment of Neuropsycholog-
ical Status (RBANS, Form A) [35] was individually administered to
measure cognitive functioning. The RBANS is comprised of 12
subtests that are used to calculate 5 age-adjusted index scores and a
total score. Test indices are Immediate Memory (comprised of List
Learning and Story Memory tasks); Visuospatial/Constructional
(comprised of Figure Copy and Line Orientation tasks); Language
(comprised of Picture Naming and Semantic Fluency tasks);
Attention (comprised of Digit Span and Coding tasks); and Delayed
Memory (comprised of List Recall, Story Recall, Figure Recall, and
List Recognition tasks). Our group previously translated RBANS
into Chinese and the clinical validity and its test-retest reliability
established among controls and schizophrenic patients [36].
Each subject came in the testing room on a separate day to be
introduced to our research center by a research member and a
proper training session had been performed for individual to
become acclimated to the testing environment and computerized
tasks. In order to reduce or eliminate the withdrawal effect of
smoking that may worsen cognitive functioning in individuals who
smoked cigarettes, participants who smoked were allowed to
smoke cigarettes prior to testing and during breaks. Breaks were
taken on request at the end of each domain test of the RBANS,
thus participants were not in a state of nicotine withdrawal.
Patient psychopathology was assessed using the Positive and
Negative Syndrome Scale (PANSS), which was measured by four
psychiatrists who had simultaneously attended a training session in
the use of the PANSS before the study began. Medication side
effects were assessed by the same clinical psychiatrists. Parkinson-
ism and akathisia were measured with the Simpson and Angus
Extrapyramidal Symptom Rating Scale (SAES), and tardive
dyskinesia with the Abnormal Involuntary Movement Scale
(AIMS). After training, repeated assessment showed that an inter
observer correlation coefficient greater than 0.8 was maintained
for the PANSS, SAES, and AIMS total score.
Statistical Analysis
Demographic and clinical variables of the smoker and non-
smoker groups were compared using t-test, analysis of variance
(ANOVA) for continuous variables and chi-squared for categorical
variables. We compared RBANS scores among the four groups
using analysis of variance (ANOVA). Fisher’s least significant
difference (LSD) test was used to perform post-hoc pair-wise
between-group comparisons. When significance was found in
ANOVA, the effects of the relevant variables were added to the
analysis model as covariants. Effect sizes were also calculated for
the two-way comparisons. Bonferroni corrections were applied to
each test to adjust for multiple testing. The relationship between
the RBANS and other variables, such as PANSS, years of
education, age of onset, hospitalization, antipsychotic treatment,
anticholinergic drugs, smoking status and nicotine dependence
shown on FTND, and side effects in the patients were examined
by multivariate regression analyses. In these analyses, all variables
were initially entered simultaneously to determine the overall
influence, and then backward stepwise procedures were employed
to determine the significant associations. SPSS version 15.0 was
used to do all statistical analysis. Data were presented as mean and
standard deviation (mean6SD). All p values were 2 tailed with
significance level set at 0.05.
Results
Table 1 shows the demographic data of schizophrenia and
normal controls. There were no significant differences in age and
education between patients and normal controls (both p.0.05).
There was significant difference in smoking rates between the
patients and normal controls (x
2=40.5, df=2, p,0.001). Com-
pared to normal controls, the schizophrenic patients had a higher
prevalence of current smoking (x
2=38.6, df=1, p,0.0001), and
lower frequency of smoking cessation (x
2=13.1, df=1,
p,0.0001).
As shown in Table 2 for the schizophrenic patients alone,
smokers were older (p,0.01), and had more hospitalizations.
Smokers also had significantly lower levels of negative symptoms
(p,0.004). After controlling for the type, the dose (chlorpromazine
equivalent) and duration of treatment of antipsychotic drugs, as
well as the other related variables such as age, and the number of
hospitalization, the significant difference in negative symptoms
between smokers and non-smokers remained (p,0.01). We did
not find significant differences in any other variables between
smokers and nonsmokers (all p.0.05).
The following variables were significant (P,0.05) predictors of
the RBANS total score in the schizophrenia patients: PANSS
negative symptoms, years of education, PANSS total score,
hospitalization times, age at schizophrenia onset, PANSS general
psychopathology, antipsychotic types (atypical vs. typical drugs),
anticholinergic drugs, smoking status (smokers vs. non-smoker),
FTND total score and Simpson-Angus Extrapyramidal Symp-
toms. While age was not correlated with the total RBANS, age
showed a significant negative association with immediate memory
(r=20.13, df=1, 580. p,0.002) and attention (r=20.11,
df=1,580, p,0.005). Using multivariate regression analysis the
following variables were independently associated with the
RBANS total score: years of education (t=7.8, p=0.0001),
PANSS negative symptom score (t=23.8, p=0.001), age at
schizophrenia onset (t=3.0, p=0.003), and number of hospital-
izations (t=22.1, p=0.04). These factors together predicted 28%
of the variance of the RBANS total score and were entered into
the regression analyses in comparing cognitive functioning in
smokers vs non-smokers.
Cognitive Functioning in Smokers and Non-smokers:
Case-Control Comparison
RBANS total and index scores of 456 smokers with schizo-
phrenia, 124 nonsmokers with schizophrenia, 96 control smokers
and 79 control nonsmokers are shown in Table 3. ANOVA
revealed that diagnosis (patient vs control) differences were
significant for the RBANS total scores and nearly all of its five
index scores (all p,0.001) except for the Visuospatial/Construc-
tional Index (p=0.07). Pair-wise post hoc comparisons showed
significant differences in the RBANS total score and all index
scores (all p,0.05) between the schizophrenic and control non-
smokers (all p,0.0001) with effect sizes ranging from 0.96 to 1.39,
and between the schizophrenic and control smokers (all p,0.001)
except for the Visuospatial/Constructional index (p.0.05) with
effect sizes ranging from 0.36 to 1.26 (Table 4).
ANOVA also revealed overall main effects for smoking in the
RBANS total score (F=6.09, df=1, 751, p=0.014), and
immediate memory index (F=6.04, df=1, 751, p=0.014).
Smokers performed worse than nonsmokers on these domains.
Furthermore, we examined smokers and nonsmokers separately
in the patient and control groups (Table 4). The schizophrenic
smoker group scored lower than the schizophrenic non-smoker
group on the RBANS total score (p,0.05) and the Visuospatial/
Constructional index (p,0.005), and a trend toward a significant
difference on the Immediate Memory index (p=0.057).
Because of the relatively older age, chronic symptoms, long
history of antipsychotic treatment and multiple hospitalizations in
Smoking, Cognition and Schizophrenia
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cognitive performance. After controlling for age, number of
hospitalizations, PANSS total score and negative symptom sub-
scores, as well as antipsychotic drugs and anticholinergic drugs
among the patients, both the overall RBANS and the Visuospa-
tial/Constructional index remained significant. Similarly, the
control smoker group scored lower than the control non-smoker
group on the Immediate Memory index (p,0.05) and the RBANS
total score (p,0.05) after controlling for age, which was negatively
correlated with both immediate memory (r=20.25, df=1,175,
p,0.001) and total RBANS score (r=20.24, df=1,175,
p,0.001) among the controls.
Discussion
To our knowledge this is the first study to compare the cognitive
functioning of smokers and non-smokers in both schizophrenia
patients and healthy controls within a Chinese sample. We found
significantly lower cognitive scores on the RBANS and nearly all
of its five subscales except for the Visuospatial/Constructional
index and a total score of RBANS than normal controls.
Furthermore, we found significant differences in some domains
of the RBANS between smoker and non-smoker groups with and
without schizophrenia. Our study also showed that the smoking
schizophrenia group consistently performed the poorest on the
cognitive domains of the RBANS.
Schizophrenia had significantly lower cognitive performance on
nearly all of its five subscales except for the Visuospatial/
Constructional index and a total score of RBANS than normal
controls. The difference in the RBANS total score between
schizophrenia patients and normal controls amounted to approx-
imately 17 points and 7 points after adjusting for confounds (i.e.
education and age). These results are consistent with the majority
of studies assessing cognitive performance in patients with
schizophrenia and in particular with a recent USA study by
Dickerson [37]. However, Dickerson’s study also found a
significant difference on the Visuospatial/Constructional index.
This difference may reflect the different demographic and clinical
states of the two samples, since Dickerson included female
outpatients stabilized on psychotropic medication for as little as
3 weeks. In contrast, our exclusively male inpatient sample was on
stable antipsychotic medications for at least 12 months. Our
patients were also older and less educated. While our controls were
matched on age, their controls were substantially younger likely
leading to better performance on the RBANS tests (46 vs 36 years
old). The importance of these gender, age and education effects on
the RBANS profiles of subtests among schizophrenia was
emphasized in a recent study of this instrument [38].
Further, performance on some measures of cognitive function
was inferior to that of non-smokers in both schizophrenic and
control groups, which was in contrast to our original expectation.
A previous study by Jockers-Scheru ¨bl et al [4] showed that regular
cannabis abuse prior to the first psychotic episode improved
cognition in some tests in schizophrenic patients, but deteriorated
test performance in healthy controls, suggesting that regular
cannabis abuse may have a different effect on cognitive function in
schizophrenic patients and healthy controls. However, in our
present study, smokers appear to display decreased cognitive
Table 2. Characteristics of Smoking and Nonsmoking Schizophrenic Patients.
Item Smokers N=456 Non-smokers N=124 t or X
2 df p
Age (yrs) 48.669.5 46.3611.1 2.43 1,578 ,0.01
Age at onset (yrs) 23.464.9 23.564.9 0.15 1,572 ns
Education (yrs) 9.864.8 9.263.6 0.79 1,569 ns
Number of hospitalizations 4.762.9 3.562.4 2.78 1,560 ,0.002
Subtypes of Schizophrenia 0.32 4 Ns
Paranoid type 142(31.1%) 40(32.3%)
Disorganized type 40 (8.8%) 10(8.1%)
Undifferentiated type 31 (6.8%) 7(5.6%)
Residual type 233 (51.1%) 64(51.6%)
Catatonic type 10 (2.2%) 3(2.4%)
Antipsychotic types 0.78 1 0.38
Typical 113(24.8%) 26(21.0%)
Atypical 343(75.2%) 98(79.0%)
Neuroleptic dose (chlorpromazine
equivalents, mg/day)
4726458 4256264 1.25 1,568 ns
PANSS total score 61.1616.6 63.2617.3 21.68 1,560 ns
P subscore 12.965.9 12.665.6 0.53 1,560 ns
N subscore 22.367.3 24.468.4 22.97 1,560 0.004
G subscore 25.966.5 26.267.1 20.99 1,560 ns
Parkinsonism score 1.462.0 2.162.2 21.76 1,561 ns
AIMS total score 4.964.6 4.764.8 0.42 1,560 ns
BMI (kg/m
2) 24.663.8 24.864.3 20.68 1,252 ns
Note: PANSS=Positive and Negative Symptom Scale; P=PANSS positive symptom subscale; N=PANSS negative symptom subscale; G=PANSS general
psychopathology subscale. AIMS=Abnormal Involuntary Movement Scale (AIMS). BMI=body mass index.
doi:10.1371/journal.pone.0036563.t002
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subject. Whether the different substance abuses may produce the
differential effects on the cognitive functions of schizophrenic
patients and healthy controls deserves the further investigation.
Nicotine is currently being used to treat Alzheimer’s disease
(AD) and Parkinson’s disease (PD), and the beneficial effects of
nicotine have been attributed to an up-regulation of nicotinic
acetylcholine receptors (nAChRs), or possibly a protection from
the neurotoxicity induced by free radicals [39,40]. However,
nicotine also can produce neuronal toxicity [41]. It has shown that
chronic cigarette smoking is a potent stimuli of oxidative processes
including increased free radical production and antioxidant
depletion [42]. For example, nicotine has decreased glutathione
(GSH) levels and increased malondialdehyde (MDA), an indicator
of lipid peroxidation in Chinese hamster ovary cells [41,42].
Homogenized rat pancreas showed a positive correlation between
nicotine dose and lipid peroxidation, and this lipid peroxidation
from nicotine was abolished by adding SOD and catalase [43].
Also, in human cigarette smoking has increased lipid peroxidation
and impaired antioxidant systems [44]. Increased levels of serum
MDA and decreased paraoxonase activities were found in healthy
smokers [45]. Thus, smoking may enhance oxidative stress not
only through the production of reactive oxygen radicals in smoker,
but also through weakening of the antioxidant defense systems.
Overall, nicotine’s effects may be dose dependent, and low dose
nicotine may be an antioxidant and be neuroprotective, whereas
high dose nicotine may induce neurotoxicity through oxidative
stress and cellular injury [46]. In addition, the other 4700
components of tobacco smoke include a variety of carcinogens as
well as other toxic compounds such as carbon monoxide, heavy
metals and cyanide, which are neurotoxic [47], and could account
for some of the cognitive, intellectual, and behavioral impairments
in the nondemented elderly [48], and in children [49]. One recent
study reported that using event-related functional MRI (fMRI),
prefrontal attentional network activity was significantly reduced in
smokers compared to nonsmokers in young adults. Furthermore,
in smokers, the history of smoking duration (years) was found to be
directly related to the extent of diminished attentional network
activity, suggesting that chronic nicotine abuse may be sufficient to
exert long-lasting neurotoxic effects on brain function of adoles-
cents and young adults [50]. Taken together, cognitive impair-
ment in both schizophrenia and controls who smoke in our present
study may be associated with neuronal toxicity produced by
nicotine, especially at high dose.
In this study we also found that the schizophrenic smokers
displayed significantly lower negative symptoms. This finding
replicates earlier work in schizophrenic patients from western
regions [51], but is not consistent with others [52]. We postulate
that the neurobiological mechanism for our finding of lower
negative symptoms in smokers than non-smokers with schizophre-
nia might be associated with the increased dopamine (DA)
function caused by cigarette smoking. Nicotinic acetylcholine
receptors have been identified on mesolimbic and nigrostriatal
dopaminergic neurons [53]. In rats, acute administration of
nicotine stimulates release of dopamine in the striatum and
nucleus accumbens by acting on presynaptic nicotine receptors
[54] and chronic nicotine treatment decreases dopamine catab-
olism in the dorsal striatum [55]. Since the negative symptoms of
schizophrenia are associated with hypoactivity of dopaminergic
systems, smoking may lessen negative symptoms by increasing
dopamine in the nucleus accumbens [56]. However, this is only
our speculation. The exact mechanisms for association between
smoking and reduced negative symptoms deserve further investi-
gation.
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study. First, this is a cross-sectional study design and cannot show
direct causality of smoking, whether beneficial or harmful, in
patients with schizophrenia. Second, the ability to generalize our
study is limited by our sample of chronically hospitalized male
patients, who had more severe psychopathology and longer
duration of illness than typical psychotic outpatients or first
episode and drug-naı ¨ve patients with schizophrenia. Third, these
patients had a wide age range including older adults aged upwards
of 75 years old. The sample was in general an older one with the
mean age of 48 and standard deviation of 10 years. The impact of
aging on cognitive decline is clear. In the control group, age had a
significant negative association with attention, immediate memory
and RBANS total score; in the patient group, age was negatively
associated with immediate memory and attention. Also, these
patients had a long history of almost 20 years of treatment with
antipsychotics, which may have influenced the effects of smoking
to some degree. However, after statistical control for these effects
of age and antipsychotic treatment, the association between
smoking and cognition remained significant. Nevertheless, analysis
in a younger and a less chronic patient population would be
worthwhile. Fourth, our sample was limited to only males and can
not be applied to females. Fifth, no drug screening was performed
among the subjects in the study which would have been prudent
since use of non-prescription drugs definitely has an impact on
performance on cognitive tasks [57]. Sixth, the participants who
smoked were allowed to smoke cigarettes during breaks in the
cognitive testing in order to avoid the effect of nicotine withdrawal;
however, a formal test of nicotine withdrawal was not included.
We also did not record any data about the numbers of cigarettes
smoked during breaks for each group. Future studies might look at
whether the schizophrenics seek out more cigarettes per session
than controls.
In conclusion, our results show that smoking is associated with
significant cognitive impairment in both schizophrenic patients
and controls. However, schizophrenic patients who smoked
displayed significantly fewer negative symptoms. These results
suggest that the benefits of smoking for those with schizophrenia
may be limited to certain aspects of a given clinical phenotype
such as negative symptoms, but not to cognitive functioning.
Further studies in first-episode and drug naı ¨ve patients with
schizophrenia would help clarify the interrelationship between
clinical symptoms, cognitive functioning and smoking.
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